Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
NCT ID: NCT00119262
Last Updated: 2014-05-15
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
226 participants
Study Classification
INTERVENTIONAL
Study Start Date
2005-10-31
Study Completion Date
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with more than one chemotherapy drug (combination chemotherapy), may be a better way to block tumor growth.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NCT00887536
Breast Cancer
COMPLETED
PHASE3
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
NCT00433511
Breast Adenocarcinoma
ACTIVE_NOT_RECRUITING
PHASE3
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
NCT00436709
Breast Cancer
UNKNOWN
NA
Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
NCT00055861
Recurrent Breast Cancer
Stage IV Breast Cancer
COMPLETED
PHASE2
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
NCT00546156
Breast Cancer
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To determine the incidence of clinically apparent cardiac dysfunction in patients with lymph node positive breast cancer treated with bevacizumab and dose dense doxorubicin/cyclophosphamide followed by paclitaxel (ddAC \> T).
SECONDARY OBJECTIVES:
I. To evaluate changes in LVEF during treatment. II. To evaluate non-cardiac toxicity.
OUTLINE: This is a non-randomized, multicenter study. Patients are sequentially assigned to 1 of 2 treatment arms.
Arm A: Patients receive doxorubicin IV, cyclophosphamide IV over 20-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Patients also receive filgrastim (G-CSF) subcutaneously (SQ) on days 2-11 or pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients then receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1. Patients also receive G-CSF or pegfilgrastim as above. Treatment with paclitaxel, bevacizumab, and G-CSF or pegfilgrastim repeats every 14 days for 4 courses. Patients then receive bevacizumab alone every 14 days for up to 18 courses.
Arm B: Patients receive doxorubicin, cyclophosphamide, and G-CSF or pegfilgrastim as in group I. Patients then receive paclitaxel, bevacizumab, and G-CSF or pegfilgrastim as in group I. Patients then receive bevacizumab alone every 14 days for up to 22 courses.
Treatment in both groups continues in the absence of disease recurrence or unacceptable toxicity.
Patients who require radiotherapy (post-lumpectomy) or who plan radiotherapy at the discretion of the investigator (post-mastectomy) undergo radiotherapy beginning within 6 weeks after the completion of chemotherapy.
Premenopausal patients with estrogen receptor (ER) and/or progesterone receptor (PR) positive disease receive oral tamoxifen once daily for 5 years beginning at the time of radiotherapy or within 6 weeks after the completion of chemotherapy. Postmenopausal patients with ER and/or PR positive disease receive an aromatase inhibitor (e.g., anastrozole, letrozole, or exemestane) or tamoxifen followed by an aromatase inhibitor once daily for up to 10 years.
After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for up to 3 years from study entry.
ACCRUAL: A total of 226 patients (104 on arm A and 122 on arm B) were accrued for this study.
I. To determine the incidence of clinically apparent cardiac dysfunction in patients with lymph node positive breast cancer treated with bevacizumab and dose dense doxorubicin/cyclophosphamide followed by paclitaxel (ddAC \> T).
SECONDARY OBJECTIVES:
I. To evaluate changes in LVEF during treatment. II. To evaluate non-cardiac toxicity.
OUTLINE: This is a non-randomized, multicenter study. Patients are sequentially assigned to 1 of 2 treatment arms.
Arm A: Patients receive doxorubicin IV, cyclophosphamide IV over 20-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Patients also receive filgrastim (G-CSF) subcutaneously (SQ) on days 2-11 or pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients then receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1. Patients also receive G-CSF or pegfilgrastim as above. Treatment with paclitaxel, bevacizumab, and G-CSF or pegfilgrastim repeats every 14 days for 4 courses. Patients then receive bevacizumab alone every 14 days for up to 18 courses.
Arm B: Patients receive doxorubicin, cyclophosphamide, and G-CSF or pegfilgrastim as in group I. Patients then receive paclitaxel, bevacizumab, and G-CSF or pegfilgrastim as in group I. Patients then receive bevacizumab alone every 14 days for up to 22 courses.
Treatment in both groups continues in the absence of disease recurrence or unacceptable toxicity.
Patients who require radiotherapy (post-lumpectomy) or who plan radiotherapy at the discretion of the investigator (post-mastectomy) undergo radiotherapy beginning within 6 weeks after the completion of chemotherapy.
Premenopausal patients with estrogen receptor (ER) and/or progesterone receptor (PR) positive disease receive oral tamoxifen once daily for 5 years beginning at the time of radiotherapy or within 6 weeks after the completion of chemotherapy. Postmenopausal patients with ER and/or PR positive disease receive an aromatase inhibitor (e.g., anastrozole, letrozole, or exemestane) or tamoxifen followed by an aromatase inhibitor once daily for up to 10 years.
After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for up to 3 years from study entry.
ACCRUAL: A total of 226 patients (104 on arm A and 122 on arm B) were accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Male Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (combination chemotherapy, 18 courses of bevacizumab)
See detailed description.
Group Type
EXPERIMENTAL
doxorubicin hydrochloride
Intervention Type
DRUG
Given IV
cyclophosphamide
Intervention Type
DRUG
Given IV
bevacizumab
Intervention Type
BIOLOGICAL
Given IV
paclitaxel
Intervention Type
DRUG
Given IV
filgrastim
Intervention Type
BIOLOGICAL
Given SC
pegfilgrastim
Intervention Type
BIOLOGICAL
Given SC
radiation therapy
Intervention Type
RADIATION
Undergo radiation therapy
tamoxifen citrate
Intervention Type
DRUG
Given orally
aromatase inhibition therapy
Intervention Type
DRUG
Receive aromatase inhibition therapy
Arm II (combination chemotherapy, 22 courses of bevacizumab)
See detailed description.
Group Type
ACTIVE_COMPARATOR
doxorubicin hydrochloride
Intervention Type
DRUG
Given IV
cyclophosphamide
Intervention Type
DRUG
Given IV
bevacizumab
Intervention Type
BIOLOGICAL
Given IV
paclitaxel
Intervention Type
DRUG
Given IV
filgrastim
Intervention Type
BIOLOGICAL
Given SC
pegfilgrastim
Intervention Type
BIOLOGICAL
Given SC
radiation therapy
Intervention Type
RADIATION
Undergo radiation therapy
tamoxifen citrate
Intervention Type
DRUG
Given orally
aromatase inhibition therapy
Intervention Type
DRUG
Receive aromatase inhibition therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
doxorubicin hydrochloride
Given IV
Intervention Type
DRUG
cyclophosphamide
Given IV
Intervention Type
DRUG
bevacizumab
Given IV
Intervention Type
BIOLOGICAL
paclitaxel
Given IV
Intervention Type
DRUG
filgrastim
Given SC
Intervention Type
BIOLOGICAL
pegfilgrastim
Given SC
Intervention Type
BIOLOGICAL
radiation therapy
Undergo radiation therapy
Intervention Type
RADIATION
tamoxifen citrate
Given orally
Intervention Type
DRUG
aromatase inhibition therapy
Receive aromatase inhibition therapy
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
ADM
ADR
Adria
Adriamycin PFS
Adriamycin RDF
CPM
CTX
Cytoxan
Endoxan
Endoxana
anti-VEGF humanized monoclonal antibody
anti-VEGF monoclonal antibody
Avastin
rhuMAb VEGF
Anzatax
Asotax
TAX
Taxol
G-CSF
Neupogen
Filgrastim SD-01
GCSF-SD01
Neulasta
SD-01 sustained duration G-CSF
irradiation
radiotherapy
therapy, radiation
Nolvadex
TAM
tamoxifen
TMX
inhibition therapy, aromatase
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed adenocarcinoma of the breast with involvement of at least one axillary or internal mammary lymph node on routine histologic examination with hematoxylin and eosin staining; NOTE: patients with axillary or internal mammary node involvement only demonstrated by immunohistochemistry are not eligible
* Patients must have completed definitive breast surgery including total mastectomy and axillary dissection (modified radical mastectomy), total mastectomy and sentinel node biopsy, lumpectomy and axillary dissection, or lumpectomy and sentinel node biopsy; NOTE: axillary dissection is strongly encouraged in patients with lymph node involvement identified on sentinel node biopsy
* Margins of lumpectomy or mastectomy must be histologically free of invasive breast cancer and ductal carcinoma in situ (DCIS); patients with resection margins positive for lobular carcinoma in situ (LCIS) are eligible
* (ARM A ONLY) Interval between last surgery for breast cancer (lumpectomy, mastectomy, sentinel node biopsy, axillary dissection or re-excision of lumpectomy margins) and D1 must be \> 28 days and =\< 84 days
* ECOG performance status of 0-2
* Absolute neutrophil count \>= 1000/mm\^3
* Platelet count \>= 100,000/mm\^3
* Total bilirubin =\< 1.5 mg/dL
* AST =\< 2 upper limit of normal
* Serum creatinine =\< 1.5 mg/dL
* Urine protein: creatinine ratio \< 1.0
* PT INR =\< 1.5
* PTT =\< 1.5 x normal
* LVEF \>= institutional limits of normal by MUGA or ECHO
* Prior to registration the investigator must specify if radiation is planned; patients who have undergone a lumpectomy must receive radiation; post-mastectomy radiation is at the investigator's discretion
* Patients with HER2+ (3+ by IHC or FISH+) breast cancer are not eligible and should be treated with a trastuzumab-based adjuvant therapy
* Patients with synchronous bilateral breast cancer (diagnosed within one month) are eligible if the higher TMN stage tumor meets the eligibility criteria for this trial
* Patients must not have clinical evidence of inflammatory disease or fixed axillary nodes (N2) at diagnosis
* Patients must not have received prior cytotoxic chemotherapy, hormonal therapy or radiation for this breast cancer; prior treatment with an anthracycline, anthracenedione or taxane for any condition is not allowed; NOTE: prior use of tamoxifen for chemoprevention is allowed but must be discontinued at study entry; similarly prior raloxifene use is allowed but must be discontinued at study entry
* Patients must not have had a major surgical procedure within 4 weeks of entry; NOTE: non-operative biopsy or placement of a vascular access device is not considered a major surgery
* Patients must not have clinically significant cardiovascular disease including:
* New York Heart Association (NYHA) grade II or greater congestive heart failure
* Grade II or greater peripheral vascular disease
* Uncontrolled hypertension defined as SBP \> 160 or DBP \> 90
* Any prior history of cerebrovascular disease including TIA or stroke
* Patients must not require therapeutic anticoagulation; patients with a history of deep venous thrombosis or pulmonary embolism are not eligible; NOTE: prophylactic use of anticoagulants to maintain patency of a vascular assess device is permitted
* Patients may not require regular use of aspirin (daily for \>= 10 days at doses of \> 325 mg/day) or regular therapeutic doses of other nonsteroidal anti-inflammatory agents known to inhibit platelet function; additionally, patients using any of the following drugs known to inhibit platelet function are not eligible: dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and cilostazol (Pletal); NOTE: regular use of Cox-2 inhibitors is permitted; NOTE: low-dose aspirin is permitted
* Patients must not have a non-healing wound or fracture; patients with an abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months are excluded
* Patients must not have hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products or other recombinant human antibodies
* Patients who have experienced myocardial infarction or unstable angina within 12 months are excluded
* Patients who have had experienced an arterial thrombotic event within 12 months are excluded
* Patients must not have uncontrolled or clinical significant arrhythmia
* Women must not be pregnant or breast-feeding due to the potential harmful effects of bevacizumab on the developing fetus; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
* Women of childbearing potential and sexually active males are required to use an accepted and effective method of contraception while on study and for at least 3-4 months after the last dose of bevacizumab
* Patients must have completed definitive breast surgery including total mastectomy and axillary dissection (modified radical mastectomy), total mastectomy and sentinel node biopsy, lumpectomy and axillary dissection, or lumpectomy and sentinel node biopsy; NOTE: axillary dissection is strongly encouraged in patients with lymph node involvement identified on sentinel node biopsy
* Margins of lumpectomy or mastectomy must be histologically free of invasive breast cancer and ductal carcinoma in situ (DCIS); patients with resection margins positive for lobular carcinoma in situ (LCIS) are eligible
* (ARM A ONLY) Interval between last surgery for breast cancer (lumpectomy, mastectomy, sentinel node biopsy, axillary dissection or re-excision of lumpectomy margins) and D1 must be \> 28 days and =\< 84 days
* ECOG performance status of 0-2
* Absolute neutrophil count \>= 1000/mm\^3
* Platelet count \>= 100,000/mm\^3
* Total bilirubin =\< 1.5 mg/dL
* AST =\< 2 upper limit of normal
* Serum creatinine =\< 1.5 mg/dL
* Urine protein: creatinine ratio \< 1.0
* PT INR =\< 1.5
* PTT =\< 1.5 x normal
* LVEF \>= institutional limits of normal by MUGA or ECHO
* Prior to registration the investigator must specify if radiation is planned; patients who have undergone a lumpectomy must receive radiation; post-mastectomy radiation is at the investigator's discretion
* Patients with HER2+ (3+ by IHC or FISH+) breast cancer are not eligible and should be treated with a trastuzumab-based adjuvant therapy
* Patients with synchronous bilateral breast cancer (diagnosed within one month) are eligible if the higher TMN stage tumor meets the eligibility criteria for this trial
* Patients must not have clinical evidence of inflammatory disease or fixed axillary nodes (N2) at diagnosis
* Patients must not have received prior cytotoxic chemotherapy, hormonal therapy or radiation for this breast cancer; prior treatment with an anthracycline, anthracenedione or taxane for any condition is not allowed; NOTE: prior use of tamoxifen for chemoprevention is allowed but must be discontinued at study entry; similarly prior raloxifene use is allowed but must be discontinued at study entry
* Patients must not have had a major surgical procedure within 4 weeks of entry; NOTE: non-operative biopsy or placement of a vascular access device is not considered a major surgery
* Patients must not have clinically significant cardiovascular disease including:
* New York Heart Association (NYHA) grade II or greater congestive heart failure
* Grade II or greater peripheral vascular disease
* Uncontrolled hypertension defined as SBP \> 160 or DBP \> 90
* Any prior history of cerebrovascular disease including TIA or stroke
* Patients must not require therapeutic anticoagulation; patients with a history of deep venous thrombosis or pulmonary embolism are not eligible; NOTE: prophylactic use of anticoagulants to maintain patency of a vascular assess device is permitted
* Patients may not require regular use of aspirin (daily for \>= 10 days at doses of \> 325 mg/day) or regular therapeutic doses of other nonsteroidal anti-inflammatory agents known to inhibit platelet function; additionally, patients using any of the following drugs known to inhibit platelet function are not eligible: dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and cilostazol (Pletal); NOTE: regular use of Cox-2 inhibitors is permitted; NOTE: low-dose aspirin is permitted
* Patients must not have a non-healing wound or fracture; patients with an abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months are excluded
* Patients must not have hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products or other recombinant human antibodies
* Patients who have experienced myocardial infarction or unstable angina within 12 months are excluded
* Patients who have had experienced an arterial thrombotic event within 12 months are excluded
* Patients must not have uncontrolled or clinical significant arrhythmia
* Women must not be pregnant or breast-feeding due to the potential harmful effects of bevacizumab on the developing fetus; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
* Women of childbearing potential and sexually active males are required to use an accepted and effective method of contraception while on study and for at least 3-4 months after the last dose of bevacizumab
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kathy Miller
Role: PRINCIPAL_INVESTIGATOR
Eastern Cooperative Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eastern Cooperative Oncology Group
Boston, Massachusetts, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2012-02977
Identifier Type: REGISTRY
Identifier Source: secondary_id
E2104
Identifier Type: OTHER
Identifier Source: secondary_id
E2104
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-02977
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Phase II Bevacizumab + Tax In Advanced Breast Cancer
NCT00027885
COMPLETED
PHASE2
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
NCT00004125
COMPLETED
PHASE3
Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer
NCT00016549
COMPLETED
PHASE2
Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer
NCT00446030
COMPLETED
PHASE2
Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer
NCT00364611
COMPLETED
PHASE2
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
NCT00320541
COMPLETED
PHASE2
Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
NCT00217672
COMPLETED
PHASE2
Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
NCT00365365
COMPLETED
PHASE2
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
NCT00861705
COMPLETED
PHASE2
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
NCT01288261
COMPLETED
PHASE1
Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
NCT01254526
COMPLETED
PHASE1
Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
NCT00365417
COMPLETED
PHASE2
Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer
NCT01190345
COMPLETED
PHASE2
Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema
NCT00318513
UNKNOWN
PHASE1
A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
NCT01722968
COMPLETED
PHASE2
Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
NCT00203502
COMPLETED
PHASE2
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
NCT00203372
COMPLETED
PHASE2
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
NCT00856492
COMPLETED
PHASE2
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
NCT00785291
COMPLETED
PHASE3
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
NCT01285466
COMPLETED
PHASE1
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
NCT01959490
COMPLETED
PHASE2
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
NCT00408408
UNKNOWN
PHASE3
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
NCT00305825
COMPLETED
PHASE2
BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer
NCT01288092
WITHDRAWN
PHASE2
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
NCT00002679
COMPLETED
PHASE2